Glyciphage-G 1 Tablet PR contains a combination of Glimepiride (1 mg) and Metformin (500 mg), formulated for the management of type 2 diabetes mellitus. Glimepiride is a sulfonylurea class antidiabetic agent that stimulates pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glycemic control. The combination of these two agents provides a complementary mechanism of action, making Glyciphage-G effective in patients inadequately controlled by diet and exercise alone or monotherapy. This medication is indicated for adults with type 2 diabetes who require dual therapy to achieve optimal blood glucose regulation. Glyciphage-G should be used alongside lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction and conditions predisposing to hypoxia. Glyciphage-G 1 Tablet PR offers a sustained-release formulation to improve patient compliance and maintain steady plasma concentrations.